Cargando…
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16–23 years) were enrolled in a randomised, placebo-controlled study of a...
Autores principales: | Villa, L L, Costa, R L R, Petta, C A, Andrade, R P, Paavonen, J, Iversen, O-E, Olsson, S-E, Høye, J, Steinwall, M, Riis-Johannessen, G, Andersson-Ellstrom, A, Elfgren, K, Krogh, G von, Lehtinen, M, Malm, C, Tamms, G M, Giacoletti, K, Lupinacci, L, Railkar, R, Taddeo, F J, Bryan, J, Esser, M T, Sings, H L, Saah, A J, Barr, E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360730/ https://www.ncbi.nlm.nih.gov/pubmed/17117182 http://dx.doi.org/10.1038/sj.bjc.6603469 |
Ejemplares similares
-
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
por: Joura, Elmar A, et al.
Publicado: (2012) -
A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
por: Ellsworth, G.B., et al.
Publicado: (2018) -
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
por: Garland, Suzanne M., et al.
Publicado: (2016) -
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia
por: Lehtinen, Matti, et al.
Publicado: (2011) -
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
por: Castellsagué, X, et al.
Publicado: (2011)